Research progress of Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma

doi:10.3877/cma.j.issn.2095-2015.2024.03.017

Abstract

Abstract:

With the development of medical technology, more and more evidence shows that the occurrence of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is closely related to the infection of Helicobacter pylori (Hp). Treatment by simple eradication of Hp has become the first-line treatment for the disease. However, it has been found that most patients with gastric MALT lymphoma do not have Hp infection, and the pathogenesis, endoscopic clinical manifestations and treatment methods of HP-negative gastric MALT lymphoma are different from those of positive patients. And treatment options are controversial. In this paper, the pathogenesis, clinical manifestations and treatment of HP-negative gastric MALT lymphoma are summarized, and the future treatment is prospected, so as to provide reference for improving the cure rate of this disease and reducing the incidence of adverse reactions.

Key words: Gastric mucosa-associated lymphoid tissue lymphoma, Helicobacter pylori, Pathogenesis, Diagnosis and treatment, Prognosis

Yanan An, Duanran Wang, Tiantian Guo, Xirun Wu. Research progress of Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 268-274.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.03.017

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I03/268

Figures/Tables 6

References 43

[1]	Gu SX, Siddon AJ, Huntington SF, et al. Helicobacter pylori–negative mucosa-associated lymphoid tissue(MALT) lymphoma of the stomach: A clinicopathologic analysis [J]. Am J Clin Pathol, 2023, 160(6): 612-619.
[2]	解雅淋何春燕, 韦思琪, 等. 幽门螺杆菌根除治疗对幽门螺杆菌阴性胃MALT淋巴瘤疗效的研究进展 [J]. 胃肠病学和肝病学杂志, 2020, 29(12): 1416-1419, 1424.
[3]	Taillieu E C K, Amorim I, Gärtner F, et al. Gastric Helicobacter species associated with dogs, cats and pigs: significance for public and animal health [J]. Vet Res, 2022, 53(1): 42.
[4]	Rodríguez-Sevilla J J, Salar Antonio. Recent Advances in the Genetic of MALT Lymphomas [J]. Cancers(Basel), 2021, 14(1): 176.
[5]	Jung H, Shin D W, Cheung D Y, et al. [Clinical Impact Assessment and Utilization Prospects of the t(11: 18) Chromosomal Translocation in Gastric MALT Lymphoma in Koreans: A Single Center Retrospective Analysis [J]. KJG, 2023, 81(1): 29-35.
[6]	Kuo S H, Yeh K H, Wu M S, et al. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma [J]. Sci Rep, 2017, 7(1): 14333.
[7]	Toyoda K, Maeshima A M, Nomoto J, et al. Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results [J]. Ann Hematol, 2019, 98(7): 1675-1687.
[8]	Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy [J]. Lancet, 2001, 357(9249): 39-40.
[9]	Hiroshi Inagaki T N, Li Chunmei, Sugiyama Toshiro, et al. Gastric MALT Lymphomas Are Divided Into Three Group Based on Responsiveness to Helicobacter Pylori Eradication and Detection of API2-MALT1 Fusion [J]. Am J Surg Pathol, 2004, 28(12): 1560-1567.
[10]	Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy [J]. J Clin Oncol, 2005, 23(22): 5061-5066.
[11]	Raderer M, Streubel B, Wohrer S, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas [J]. Gut, 2005, 55(5): 616-618.
[12]	Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication [J]. J Clin Oncol, 2005, 23(31): 8018-8024.
[13]	Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment [J]. Cancer, 2006, 107(12): 2770-2778.
[14]	Taiji Akamatsu T M, Okiyama Yoko, Matsumoto Akihiro, Miyabayashi Hideharu, et al. Comparison of localized gastric mucosa-associated lymphoid tissue(MALT) lymphoma with and without Helicobacter pylori infection [J]. Helicobacter, 2006, 11(2): 86-95.
[15]	Nakamura T, Seto M, Tajika M, et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status [J]. Am J Gastroenterol, 2008, 103(1): 62-70.
[16]	Wang G, Auerbach A, Wei M, et al. t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases [J]. Mod Pathol, 2009, 22(1): 79-86.
[17]	Asano N, Iijima K, Terai S, et al. Eradication therapy is effective for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma [J]. Tohoku J Exp Med, 2012, 228(3): 223-227.
[18]	Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan [J]. Gut, 2012, 61(4): 507-513.
[19]	Choi Y J, Kim N, Paik J H, et al. Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome [J]. Helicobacter, 2013, 18(3): 197-205.
[20]	Raderer M, Wohrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up [J]. Ann Hematol, 2015, 94(6): 969-973.
[21]	Strati P, Lee S T, Teegavarupu P, et al. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma [J]. Am J Hematol, 2019, 94(6): E150-E153.
[22]	Kim S H, Soliman Y, Chitnavis V N, et al. Helicobacter Pylori-Negative MALT Lymphoma: A Series of Two Cases Presenting with Life-Threatening Upper Gastrointestinal Bleeding [J]. Case Rep Gastrointest Med, 2023, 2023: 8244696.
[23]	Raderer M, Kiesewetter B, andDu M Q. Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal [J]. Ther Adv Med Oncol, 2023, 15: 17588359231183565.
[24]	Ye Hongtao, Gong Liping, Liu Hongxiang, et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. [J]. J. Pathol, 2005, 205(3): 293–301.
[25]	Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue(MALT lymphoma) [J]. CA Cancer J Clin, 2016, 66(2): 153-171.
[26]	Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management [J]. Br J Haematol, 2015, 168(3): 317-327.
[27]	Nonaka KIK, Arai S, Nakao M, et al. A case of gastric mucosa-associated lymphoid tissue lymphoma in which magnified endoscopy with narrow band imaging was useful in the diagnosis[J]. World J Gastrointest Endosc, 2012, 16(4): 151-156.
[28]	Nakagawa S, Shimoyama T, Nakamura M, et al. The Resolution of Helicobacter suis-associated Gastric Lesions after Eradication Therapy [J]. Intern Med, 2018, 57(2): 203-207.
[29]	Park HS, Kim YJ, Yang WI, et al. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma [J]. World J Gastroenterol, 2010, 16(17): 2158-2162.
[30]	Ryu KD, Kim GH, Park SO, et al. Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience [J]. Gut Liver, 2014, 8(4): 408-414.
[31]	Gong EJ, Ahn JY, Jung HY, et al. Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma [J]. Gut Liver, 2016, 10(5): 706-713.
[32]	Kim JS, Kang SH, Moon HS, et al. Clinical Outcome of Eradication Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to H. pylori Infection Status [J]. Gastroenterol Res Pract, 2016, 2016: 6794848.
[33]	柳娟, 杜凌, 陈刚. 根除幽门螺杆菌对胃黏膜相关淋巴组织淋巴瘤疗效分析[J]. 临床消化病杂志, 2017, 29(3): 129-131.
[34]	邵龙飞, 许周毅, 梁佳毅, 等. 幽门螺杆菌感染与胃MALT淋巴瘤免疫微环境的影响及意义 [J]. 临床与实验病理学杂志, 2023, 39(6): 650-654.
[35]	Rahman SH, Chaudhry AW, Raoof S, et al. Helicobacter pylori-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Presenting as Massive Gastrointestinal Bleed [J]. Cureus, 2022, 14(9): e29125.
[36]	Kim SH, Soliman Y, Chitnavis VN, et al. Helicobacter Pylori-Negative MALT Lymphoma: A Series of Two Cases Presenting with Life-Threatening Upper Gastrointestinal Bleeding [J]. Case Rep Gastrointest Med, 2023, 2023: 8244696.
[37]	Lu SN, Huang C, Li LL, et al. Synchronous early gastric and intestinal mucosa-associated lymphoid tissue lymphoma in a Helicobacter pylori-negative patient: A case report [J]. World J Clin Cases, 2022, 10(33): 12447-12454.
[38]	Takigawa H, Yuge R, Masaki S, et al. Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy [J]. Gastric Cancer, 2021, 24(4): 937-945.
[39]	Moleiro J, Ferreira S, Lage P, et al. Gastric malt lymphoma: Analysis of a series of consecutive patients over 20 years [J]. UEG journal, 2016, 4(3): 395-402.
[40]	Li XW, Wang X, Zhan Z, et al. Evaluation of the clinical characteristics, management, and prognosis of 103 patients with gastric mucosa-associated lymphoid tissue lymphoma [J]. Oncol Lett, 2016, 11(3): 1713-1718.
[41]	Zullo Angelo, Ridola Lorenzo, De Francesco Vincenzo, et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review [J]. J Clin Gastroenterol, 2013, 47(10): 824-827.
[42]	Takigawa H, Yuge R, Miyamoto R, et al. Comprehensive Analysis of Gene Expression Profiling to Explore Predictive Markers for Eradication Therapy Efficacy against Helicobacter pylori-Negative Gastric MALT Lymphoma [J]. Cancers(Basel), 2023, 15(4): 1206.
[43]	Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type[J]. Ann Onco, 2009, 20(6): 1086-1093.

文献信息	病例总数	基因突变统计
文献信息	病例总数	总数	Hp阴性	Hp阳性
Jung H 2023^[5]	22	6	6	0
Liu H 2001^[8]	21	9	9	0
Hiroshi Inagaki 2004^[9]	115	21	11	10
Lévy M 2005^[10]	53	17	12	5
Raderer M 2005^[11]	6	1	1	0
Wundisch T2005^[12]	65	10	10	0
Nakamura S 2006^[13]	54	7	6	1
Taiji Akamatsu 2006^[14]	14	6	3	3
Nakamura T 2008^[15]	87	15	8	7
Wang G 2009^[16]	48	15	NA	NA
Asano N 2012^[17]	18	7	7	0
Nakamura S 2012^[18]	206	30	NA	NA
Choi YJ 2013^[19]	66	10	5	5
Raderer M 2015^[20]	97	3	3	0
Strati P 2019^[21]	26	3	3	0
Kim SH 2023^[22]	2	2	2	0
Takigawa H 2021^[38]	182	13	5	8
Takigawa H 2023^[42]	137	17	14	3
汇总	1219	192	105	42

文献信息	病例总数	基因突变统计
文献信息	病例总数	总数	Hp阴性	Hp阳性
Jung H 2023^[5]	22	6	6	0
Liu H 2001^[8]	21	9	9	0
Hiroshi Inagaki 2004^[9]	115	21	11	10
Lévy M 2005^[10]	53	17	12	5
Raderer M 2005^[11]	6	1	1	0
Wundisch T2005^[12]	65	10	10	0
Nakamura S 2006^[13]	54	7	6	1
Taiji Akamatsu 2006^[14]	14	6	3	3
Nakamura T 2008^[15]	87	15	8	7
Wang G 2009^[16]	48	15	NA	NA
Asano N 2012^[17]	18	7	7	0
Nakamura S 2012^[18]	206	30	NA	NA
Choi YJ 2013^[19]	66	10	5	5
Raderer M 2015^[20]	97	3	3	0
Strati P 2019^[21]	26	3	3	0
Kim SH 2023^[22]	2	2	2	0
Takigawa H 2021^[38]	182	13	5	8
Takigawa H 2023^[42]	137	17	14	3
汇总	1219	192	105	42

文献信息	例数	年龄(岁)	病灶数目(单个/多个)	发病部位(近端/远端)	病变性质(浅表型/溃疡型/结节型)	浸润深度(黏膜及黏膜下层/肌层及以下)	分期(早期/进展期)
Nakamura S 2006^[13]	10	58(41~80)	NA	7/3	溃疡/其他类型4/6	3/7	7/3
Taiji Akamatsu 2006^[14]	16	64.8(39~80)	12/4	10/2(4例弥漫)	0/16/0	14/2	14/2
Asano N 2012^[17]	18	58.5	3/15	2/16	14/0/4	NA	18/0
Choi YJ 2013^[19]	13	60.23	11/2	5/8	10/3/0	4/9	9/4
Park HS 2010^[29]	11	55.7(36~73)	5/6	2/3(6例弥漫)	溃疡/结节6/3(2例混合)	NA	NA
Ryu KD 2014^[30]	14	57	5/9	3/2(9例弥漫)	12/2/0	NA	10/4
Gong EJ 2016^[31]	28	52(48~59)	NA	12/16	20/8/0	27/1	25/3
Kim JS 2016^[32]	12	58.5	2/10	4/2(6例弥漫)	9/3/0	NA	9/3
柳娟2019^[33]	13	52(46~65)	3/10	6/1(6例弥漫)	NA	NA	4/9
汇总	135		41/56	51/53(31例弥漫)	浅表型65；溃疡型27；结节型7；其他8	48/19	96/28

文献信息	例数	年龄(岁)	病灶数目(单个/多个)	发病部位(近端/远端)	病变性质(浅表型/溃疡型/结节型)	浸润深度(黏膜及黏膜下层/肌层及以下)	分期(早期/进展期)
Nakamura S 2006^[13]	10	58(41~80)	NA	7/3	溃疡/其他类型4/6	3/7	7/3
Taiji Akamatsu 2006^[14]	16	64.8(39~80)	12/4	10/2(4例弥漫)	0/16/0	14/2	14/2
Asano N 2012^[17]	18	58.5	3/15	2/16	14/0/4	NA	18/0
Choi YJ 2013^[19]	13	60.23	11/2	5/8	10/3/0	4/9	9/4
Park HS 2010^[29]	11	55.7(36~73)	5/6	2/3(6例弥漫)	溃疡/结节6/3(2例混合)	NA	NA
Ryu KD 2014^[30]	14	57	5/9	3/2(9例弥漫)	12/2/0	NA	10/4
Gong EJ 2016^[31]	28	52(48~59)	NA	12/16	20/8/0	27/1	25/3
Kim JS 2016^[32]	12	58.5	2/10	4/2(6例弥漫)	9/3/0	NA	9/3
柳娟2019^[33]	13	52(46~65)	3/10	6/1(6例弥漫)	NA	NA	4/9
汇总	135		41/56	51/53(31例弥漫)	浅表型65；溃疡型27；结节型7；其他8	48/19	96/28

	无基因突变	存在基因突变
治疗方式	抗Hp治疗	抗Hp治疗	放射治疗
有效率	36.22%	8.77%	33.33%

Please choose a citation manager

Content to export